SCHEMBL6312910

SCHEMBL6312910

CC1=C(C#N)C(c2cccc(-c3cccnc3)c2)NC(=O)N1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
GLA P06280 3/20 0.50
GAA P10253 3/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HTT P42858 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
CYP11B2 P19099 9/20 0.41
CYP11B1 P15538 8/20 0.41
CYP1A2 P05177 3/20 0.39
STK10 O94804 1/20 0.38
SLK Q9H2G2 1/20 0.38
CYP17A1 P05093 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315155 0.89 KDM4E (0.40) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6314299 0.86 CYP11B1 (0.41) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6312851 0.84 ALDH1A1 (0.46) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6312361 0.83 ALDH1A1 (0.42) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6312597 0.81 SMN1; SMN2 (0.38) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL4988077 0.81 MAPK1 (0.55) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6316060 0.80 KDM4E (0.47) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6608080 0.78 ALDH1A1 (0.40) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL6312587 0.77 MAPK1 (0.51) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL5344446 0.77 KIF11 (0.67) ALDH1A1KDM4EGAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900214-B2 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-31 US disclosed
EP-1373223-A4 CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES BRISTOL MYERS SQUIBB CO (US) 2004-09-29 EP disclosed
EP-1373223-A1 CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES Bristol-Myers Squibb Company (US) 2004-01-02 EP disclosed
WO-2002079169-A1 CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-10 WO disclosed
US-20020143026-A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143026-A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases CCNB1, BUB1B, BUB1 ALDH1A1 980/4885KDM4E 1638/4885GLA 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.